Skip to content

Feasibility and Safety of MiWEndo-assisted Colonoscopy

Feasibility and Safety of MiWEndo-assisted Colonoscopy:Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05477836
Acronym
MiWEndo1
Enrollment
15
Registered
2022-07-28
Start date
2022-10-18
Completion date
2022-11-25
Last updated
2022-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenocarcinoma, Colorectal Adenoma, Colorectal Adenomatous Polyp, Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp

Keywords

microwave imaging, colonoscopy, early diagnosis, colorectal cancer screening

Brief summary

The study involves the planned use of a new microwave-based device during colonoscopy procedures in a small group of patients to assess the preliminary safety of its use and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies, including: phantom studies, an ex vivo study with human tissues, and an in vivo study with animal model (pig).

Detailed description

This study is designed as a single-center prospective, non-comparative, first in human pilot safety and feasibility study with few patients, whereby data will be subject to an analytical description, rather than to a statistical treatment (refer to Statistical design and analysis). In this study the principal aim is to assess the clinical safety of the device and the feasibility of its use in assisted colonoscopy. Relevant claims to verify in this study are that the device can be used without ADEs, without any change in the current clinical practice, as well as without any major difficulty by the endoscopist, neither in the preparation nor in the use of the device during exploration. In addition, the study aims to gather real clinical data with the use of the device to optimise the processing software that will be key to demonstrate MiWEndo's performance on a subsequent clinical investigation (pivotal study). Consequently, principal and secondary objectives of this investigation, are: * Principal objectives: * To assess the feasibility of performing a complete colonoscopy using the MiWEndo System. * To assess the safety of MiWEndo colonoscopy. * Secondary objectives: * To assess the perception of difficulty by the endoscopist when the device is used. * To assess the patient's comfort. * To collect data on polyp detection performance to guide possible further improvements of the software before starting the pivotal study.

Interventions

DEVICEMiWEndo-assisted colonoscopy

All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.

Sponsors

Hospital Clinic of Barcelona
CollaboratorOTHER
MiWEndo Solutions S.L.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

Traditional feasibility study, following a single-center prospective, non-comparative, with few patients design.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women older than 50 years referred for a diagnostic or surveillance colonoscopy and having signed the Informed Consent Form.

Exclusion criteria

* Patients at a high risk of having major complications as perforation or hemorrhage or in whom the possibility of performing a complete colonoscopy is reduced, including: patients with known colonic strictures, total colectomy, acute diverticulitis, inflammatory bowel disease, suspected or proven lower gastrointestinal bleeding, non-correctable coagulopathy or anticoagulant/clopidogrel therapy during procedure, inadequate bowel cleansing or previous incomplete colonoscopy. * ASA-IV patients * Urgent colonoscopy

Design outcomes

Primary

MeasureTime frameDescription
Length of colon exploredDuring the procedureIn case cecum could not be reached, the distance will be measured (in cm).
Number of incidents and adverse eventsDuring the procedure and up to 2 weeks afterTo assess the safety of MiWEndo colonoscopy using the lexicon proposed by the American Society of Gastrointestinal Endoscopy (ASGE).
Number of mural injuriesDuring the procedureTo assess the safety of MiWEndo colonoscopy according to the Sydney classification for deep mural injuries (DMI)
Rate of cecal intubationDuring the procedureTo assess the feasibility of performing a complete colonoscopy using the MiWEndo System. This parameter will be measured as complete colonoscopy (yes/no).

Secondary

MeasureTime frameDescription
Patients' comfortImmediately after the procedure and 2 weeks afterSubjective assessment from patient following the Gloucester 5-Likert scale, where 1 is no discomfort and 5 is extreme discomfort.
Time for reaching the cecum (or maximum explored colon length)During the procedureMeasured in minutes
Total time for completing the procedureImmediately after the procedureMeasured in minutes
Perception of difficultyImmediately after the procedureDifficulty by the endoscopist subjectively assessed based on a 5-points Likert scale, where 0 is not difficult and 4 is very difficult.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026